UK biotech valued at $500m will use public offering to move 5 life-extension technologies into phase 2 trials.
Juvenescence moves IPO to second half of 2020
Posted in biotech/medical
Posted in biotech/medical
UK biotech valued at $500m will use public offering to move 5 life-extension technologies into phase 2 trials.